Vertex Pharmaceuticals
VRTX
1,208 hedge funds and large institutions have $74.9B invested in Vertex Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 110 funds opening new positions, 459 increasing their positions, 467 reducing their positions, and 95 closing their positions.
26% more call options, than puts
Call options by funds: $447M | Put options by funds: $355M
16% more first-time investments, than exits
New positions opened: 110 | Existing positions closed: 95
10% more capital invested
Capital invested by funds: $68B → $74.9B (+$6.9B)
0.89% more ownership
Funds ownership: 92.35% → 93.24% (+0.89%)
2% less repeat investments, than reductions
Existing positions increased: 459 | Existing positions reduced: 467
1% less funds holding
Funds holding: 1,223 → 1,208 (-15)
14% less funds holding in top 10
Funds holding in top 10: 28 → 24 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$1.01B |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$568M |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$350M |
| 4 |
JP Morgan Chase
New York
|
+$261M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$243M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$477M |
| 2 |
Renaissance Technologies
New York
|
-$255M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$209M |
| 4 |
Man Group
London,
United Kingdom
|
-$173M |
| 5 |
Jennison Associates
New York
|
-$161M |
VRTX Hedge Fund Activity: Q1 2023 in Review
1,208 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2023, worth a combined $74.9B — up 10% from $68B a quarter earlier.
Buyers outnumbered sellers: 110 funds opened new VRTX positions and 95 closed out — a net gain of 15 holders — while 459 added to existing stakes and 467 trimmed.
The largest buyer was Capital World Investors, adding an estimated $1.01B. The largest seller was Fidelity Investments, cutting an estimated $477M.
- 1,208 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2023, down from 1,223 in Q4 2022.
- Funds reported $74.9B of Vertex Pharmaceuticals stock for Q1 2023, up 10% quarter-over-quarter.
- 110 funds opened new Vertex Pharmaceuticals positions in Q1 2023 and 95 closed out, a net change of +15 holders.
- The largest Vertex Pharmaceuticals buyer in Q1 2023 was Capital World Investors, an estimated $1.01B added.
- The largest Vertex Pharmaceuticals seller in Q1 2023 was Fidelity Investments, an estimated $477M sold.
Based on aggregated 13F filings for Q1 2023.